IHE
iShares U.S. Pharmaceuticals ETF
Price Chart
Latest Quote
$95.08
+0.96 (+1.02%)
Current Price
| Previous Close | $94.12 |
| Open | $94.97 |
| Day High | $95.78 |
| Day Low | $94.54 |
| Volume | 436,865 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.62% |
| Net Assets | $912.87M |
| Expense Ratio | 0.38% |
| Category | Health |
| Fund Family | iShares |
| Net Asset Value | $95.01 |
| Premium/Discount | 0.07% |
| Quarterly Dividend Yield | 1.62% |
| P/E Ratio | 26.63 |
| Exchange | PCX |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $92.51 |
| SMA50 | $89.68 |
| SMA200 | $83.61 |
| RSI | 71.78 |
| ATR | 1.6717 |
| Rel Volume | 3.88 |
Performance History
| Week | +1.91% |
| Month | +4.21% |
| Quarter | +13.34% |
| 6 Months | +12.55% |
| YTD | +12.74% |
| Year | +48.36% |
| 3 Years | +67.58% |
| 5 Years | +66.44% |
| 10 Years | +145.55% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $95.08 | 436,900 |
| 2026-06-23 | $94.12 | 197,000 |
| 2026-06-22 | $92.64 | 70,300 |
| 2026-06-18 | $91.88 | 172,800 |
| 2026-06-17 | $92.83 | 148,200 |
| 2026-06-16 | $93.30 | 153,900 |
| 2026-06-15 | $93.73 | 117,200 |
| 2026-06-12 | $94.47 | 44,900 |
| 2026-06-11 | $94.78 | 169,500 |
| 2026-06-10 | $93.06 | 47,700 |
| 2026-06-09 | $93.51 | 76,200 |
| 2026-06-08 | $92.31 | 140,300 |
| 2026-06-05 | $92.41 | 104,300 |
| 2026-06-04 | $92.16 | 58,300 |
| 2026-06-03 | $89.75 | 49,800 |
| 2026-06-02 | $88.72 | 61,200 |
| 2026-06-01 | $90.02 | 53,300 |
| 2026-05-29 | $91.44 | 37,000 |
| 2026-05-28 | $92.33 | 36,400 |
| 2026-05-27 | $91.59 | 79,700 |
| 2026-05-26 | $90.92 | 75,500 |
About iShares U.S. Pharmaceuticals ETF
The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The fund is non-diversified.
📰 Latest News
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks • 2026-06-10T16:00:00Z
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Zacks • 2026-06-09T13:59:00Z
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF
Barchart • 2026-06-02T19:02:50Z
Healthcare ETFs to Buy as Eli Lily Steps Into Vaccine Market With $4B Bet
Zacks • 2026-05-29T13:22:00Z
Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?
24/7 Wall St. • 2026-05-19T20:19:54Z
The Silver Tsunami: Healthcare ETFs to Buy Amid Aging US Demographics
Zacks • 2026-05-13T14:39:00Z
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Zacks • 2026-05-11T10:20:03Z
IHE- As AI Speeds Drug Research, this Pharmaceutical ETF Should Prosper
MoneyShow • 2026-05-04T10:00:00Z
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Zacks • 2026-03-30T14:40:00Z
With Two Companies Dictating Everything, IHE Is Riskier Than Most Investors Realize
24/7 Wall St. • 2026-03-24T14:07:48Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.